Handa Pharmaceuticals officially lists on the Taipei Exchange (TPEx) today (the 23rd) with an underwriting price of NT$84.33 per share. Chairman Liu Fang-yu stated that the company’s objective is to launch at least one new product annually, marking a transition into a high-growth phase as regulatory approvals accumulate.

Founded in 2014, Handa utilizes a dual-engine strategy focusing on High-Barrier Generics and 505(b)(2) New Drugs. Since turning profitable in 2023, the company has seen consistent growth, with its 2025 Q1–Q3 earnings per share (EPS) reaching NT$3.76, already surpassing the full-year results of 2024.

Key Product Portfolio:

• Marketed Products: Quetiapine XR (Schizophrenia), Dexlansoprazole DR (GERD), and Tascenso® (Multiple Sclerosis).
• New Launch: Phyrago, under US subsidiary Handa Therapeutics, launched in mid-October 2025 for Chronic Myeloid Leukemia (CML) patients requiring concomitant antacids. It has been included in the NCCN Guidelines, providing a clinical roadmap for physicians.
• Pipeline Highlight: HND-039, a multi-target oncology drug for Renal Cell Carcinoma (RCC) and Hepatocellular Carcinoma (HCC), applied for a US FDA NDA in September 2025. Utilizing a proprietary salt-based absorption system, it offers higher bioavailability at lower doses. Analysts estimate the global market for this drug at US$3 billion, with potential approval by July 2026.

Resource: 漢達今日上櫃 新劑型新藥動能接棒、獲利成長可期